Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia

Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2016, Pages 56-66

  Xiao, Alan J ^a   Miller, Benjamin W ^a   Huntington, Jennifer A ^a   Nicolau, David P ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

ceftolozane tazobactam; dose justification; epithelial lining fluid; nosocomial pneumonia; probability of target attainment; Pseudomonas aeruginosa

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; DRUG COMBINATION; PENICILLANIC ACID; TAZOBACTAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG PENETRATION; EPITHELIAL LINING FLUID; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FUNCTION; KINETICS; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NOSOCOMIAL PNEUMONIA; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PROBABILITY; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; CLINICAL TRIAL; CROSS INFECTION; DRUG COMBINATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PNEUMONIA; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CEPHALOSPORINS; CROSS INFECTION; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PENICILLANIC ACID; PNEUMONIA; YOUNG ADULT;

EID: 84954153001     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.566     Document Type: Article

References (40)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416
2. Jones RN., Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010; 51 (suppl 1): S81-S87
3. Udy AA, Roberts JA, Lipman J., How should we dose antibiotics for pneumonia in the ICU? Curr Opin Infect Dis. 2013; 26 (2): 189-195
4. Zerbaxa [prescribing information]. Lexington, MA: Cubist Pharmaceuticals Inc. 2014. http://www.zerbaxa.com/pdf/PrescribingInformation.pdf
5. Farrell DJ, Sader HS, Flamm RK, Jones RN., Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014; 43 (6): 533-539
6. Craig WA, Andes DR,. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013; 57 (4): 1577-1582
7. Drusano GL., Antimicrobial pharmacodynamics: critical interactions of "bug and drug" Nat Rev Microbiol. 2004; 2 (4): 289-300
8. Lepak AJ, Reda A, Marchillo K, Van HJ, Craig WA, Andes D,. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2014; 58 (10): 6311-6314
9. Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O., Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012; 67 (10): 2463-2469
10. Roberts JA, Paul SK, Akova M, et al., DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014; 58 (8): 1072-1083
11. Melhem M, Forrest A, Rubino C., Pharmacokinetic-pharmacodynamic (PK-PD) target attainment (TA) analyses supporting the selection of in vitro susceptibility test interpretive criteria for ceftolozane/tazobactam (TOL/TAZ) against Pseudomonas aeruginosa. Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); May 10-13, 2014; Barcelona, Spain. Poster 1743
12. Solomkin J, Hershberger E, Miller B, et al., Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015; 60 (10): 1462-1471
13. Lucasti C, Hershberger E, Miller B, et al., Multicenter, double- blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014; 58 (9): 5350-5357
14. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO., Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015; 385 (9981): 1940-1956
15. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL., Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis. 2010;51(suppl 1):S103-S110
16. Chandorkar G, Xiao A, Mouksassi S, Hershberger E, Krishna G., Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol. 2015; 55 (2): 230-239
17. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA: 2012
18. Vanscoy B, Mendes RE, Nicasio AM, et al., Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother. 2013; 57 (6): 2809-2814
19. Vanscoy B, Mendes RE, McCauley J, et al., Pharmacological basis of beta-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother. 2013; 57 (12): 5924-5930
20. Pea F, Viale P., The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis. 2006; 42 (12): 1764-1771
21. Rello J, Ulldemolins M, Lisboa T, et al., Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J. 2011; 37 (6): 1332-1339
22. Kollef MH, Morrow LE, Niederman MS, et al., Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006; 129 (5): 1210-1218
23. Tumbarello M, De Pascale G, Trecarichi EM, et al., Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med. 2013; 39 (4): 682-692
24. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I,. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012; 56 (6): 3086-3091
25. Siegel RE., The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia: are we looking in the wrong place? Chest. 1999; 116 (2): 535-538
26. Rodvold KA, George JM, Yoo L., Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011; 50 (10): 637-664
27. Li C, Du X, Kuti JL, Nicolau DP., Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007; 51 (5): 1725-1730
28. Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL., Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2011; 55 (4): 1606-1610
29. Felton TW, McCalman K, Malagon I, et al., Pulmonary penetration of piperacillin and tazobactam in critically ill patients. Clin Pharmacol Ther. 2014; 96 (4): 438-448
30. Boselli E, Breilh D, Rimmele T, et al., Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med. 2008; 36 (5): 1500-1506
31. Muller AE, Schmitt-Hoffmann AH, Punt N, Mouton JW., Monte Carlo simulations based on phase I studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study. Antimicrob Agents Chemother. 2013; 57 (5): 2047-2053
32. Roberts JA, Lipman J., Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med. 2013; 41 (2): 489-495
33. Young RJ, Lipman J, Gin T, Gomersall CD, Joynt GM, Oh TE,. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother. 1997; 40 (2): 269-273
34. Heim-Duthoy KL, Bubrick MP, Cocchetto DM, Matzke GR., Disposition of ceftazidime in surgical patients with intra-abdominal infection. Antimicrob Agents Chemother. 1988; 32 (12): 1845-1847
35. de Stoppelaar F, Stolk L, van Tiel F, Beysens A, van der Geest S, de Leeuw P., Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2000; 46 (1): 150-151
36. Binder L, Schworer H, Hoppe S, et al., Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit. 2013; 35 (1): 63-70
37. Bedikian A, Okamoto MP, Nakahiro RK, et al., Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother. 1994; 38 (1): 151-154
38. Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH., Novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob Agents Chemother. 2012; 56 (5): 2237-2240
39. Rubino C, Bhavnani SM, Steenbergen JN, Krishna G, Ambrose PG., Pharmacokinetic- pharmacodynamic (PK-PD) target attainment analyses supporting the selection of in vitro susceptibility test interpretive criteria for ceftolozane/tazobactam (TOL/TAZ) against Enterobacteriaceae. Presented at: 54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC. Poster A-1347
40. Melchers MJ, Mavridou E, Seyedmousavi S, van Mil AC, Lagarde C, Mouton JW,. Plasma and ELF pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice. Antimicrob Agents Chemother. 2015; 59 (6): 3373-3376